The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies Meeting Abstract

   


Authors: Hamlin, P.; Farber, C.; Fenske, T.; Khatcheressian, J.; Miller, C.; Munoz, J.; Patel, M.; Smith, S.; Stevens, D.; Pandey, A.; Birrell, M.; Leeds, J.; Wang, Y. L.; Coffey, G.; Curnutte, J.
Abstract Title: The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies
Meeting Title: 22nd Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 102
Issue: Suppl. 2
Meeting Dates: 2017 Jun 22-25
Meeting Location: Madrid, Spain
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2017-06-26
Start Page: 312
End Page: 313
Language: English
ACCESSION: WOS:000404127002262
PROVIDER: wos
PMCID: PMC5492673
Notes: Meeting Abstract: S773 -- Source: Wos